

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Profile of the intermolecular forces governing the interaction of drugs with mucin

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1532901> since 2016-06-29T13:09:00Z

Published version:

DOI:10.1016/j.ijpharm.2015.04.058

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in INTERNATIONAL JOURNAL OF PHARMACEUTICS, 488 (1-2), 2015, 10.1016/j.ijpharm.2015.04.058.

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

- (1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.
- (2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.
- (3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>), 10.1016/j.ijpharm.2015.04.058

The publisher's version is available at:

<http://linkinghub.elsevier.com/retrieve/pii/S037851731500366X>

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/2318/1532901>



Profile of the intermolecular forces governing the interaction of drugs with mucin

Giulia Caron, Sonja Visentin, Carlotta Pontremoli, Giuseppe Ermondi

E-mail: giulia.caron@unito.it

Tel.: +39 011 6708337

Molecular Biotechnology and Health Sciences Dept., Università degli Studi di Torino, via Quarello 15, 10135 Torino, Italy.

Abstract

The study highlights the balance of the intermolecular forces governing the interaction between drugs and mucin. The interaction strength is expressed as a retention factor k (data retrieved from the literature (Gargano et al., 2014)) obtained by a new bio-affinity chromatographic method in which the stationary phase is based on covalently immobilized mucin (porcine gastric mucin, PGM). A Quantitative Structure-Property Relationship (QSPR) between $\log k$ and 82 VolSurf+ descriptors was established and mechanistically interpreted. Results evidence how the hydrogen bonding donor (HBD) properties of solutes favor the interaction with mucin whereas the hydrogen bonding acceptor properties (HBA) are detrimental for binding.

Keywords

Absorption, mucin, QSPR, VolSurf+

Main text

Estimating the extent of oral drug absorption is a step of great value in drug candidates selection (Hughes et al., 2011). Among issues modulating drug absorption mucus penetration cannot be ignored. In fact mucus is the first barrier that drugs must overcome to be absorbed and gain access to the circulatory system (Sigurdsson et al., 2013). The major constituents of mucus are water (95-99.5%) and high molecular weight glycoproteins called mucins. (Sigurdsson et al., 2013). In the mucus these large oligomeric glycoproteins form networks which are a chemical and physical barrier that not only protect the epithelial but also limits the use of oral administered and inhalatory drugs.

Two main mechanisms limit diffusion through mucus gel: a) interaction with mucus components (i.e. electrostatic and hydrophobic interactions with mucins) and b) size filtering related to the size of the mesh spacing between the mucin fibers. Whereas the first mechanism concerns both drugs in solution and nanoparticles, the second is relevant only for nanoformulations. In 2013 the review by Sigurdsson and coworkers highlighted that no definitive picture of the nature of the molecular interactions between drug molecules and mucus components can be drawn (Sigurdsson et al., 2013). Chromatography using biomimetic stationary phases is of great relevance in early drug discovery since it is expected to provide insight for biological partition/distribution processes. (Valkó, 2004). Recently a paper reported on a bio-affinity chromatographic method which uses a novel stationary phase based on covalently immobilized mucin and explores its use as a tool to screen drugs for their affinity to mucin (Gargano et al., 2014).

Since we are interested in highlighting the nature of the interaction between drugs and mucin, we submitted the Gargano's data to a Quantitative Structure-Property Relationship (QSPR) study, which produced a statistical model. Then to extract information about the balance of intermolecular forces governing the system we used the Block Relevance (BR) analysis (Ermondi and Caron, 2012)(Caron et al., 2013).

To obtain a QSPR model we firstly transformed in the logarithmic scale the 25 experimental k values different from zero (Gargano et al., 2014). $\log k$ were then imported into VolSurf+ (VS+, version 1.0.7, <http://www.moldiscovery.com>) as response variables (Y). 82 VS+ molecular descriptors (X) were calculated for any compound using standard settings as described elsewhere (Caron et al., 2013). A relation between Y and Xs (all data are available in Table S1) was sought using the Partial Least Squares (PLS) algorithm implemented in the software. The PLS analysis results are reported in Table 1 and show that a statistically significant model was found ($R^2 = 0.91$). The validation of the model was performed by means of an internal validation procedure as discussed elsewhere (Ermondi et al., 2014). In particular, a Random Groups (RG) approach was used. A very good cross-validated correlation coefficient $Q^2(\text{RG})$ was found (0.58 in Table 1). The correlation between predicted vs experimental values is shown in the Supporting Information (R^2 about 0.70, Fig. S1). As desired, the slope is close to 1 and the intercept is close to 0.

Table 1. PLS analysis results (n = number of observations, R^2 = cumulative determination coefficient, $Q^2(\text{RG})$ = cross-validated correlation coefficient, LV = number of latent variables, $SDEP$ = standard error on the prediction).

| System | N | R^2 | $Q^2(\text{RG})$ | LV | SDEP |
|---------------|----------|-------------------------|------------------------------------|-----------|-------------|
| log k mucin | 25 | 0.91 | 0.58 | 4 | 0.38 |

To provide a mechanistic interpretation of the QSPR model we applied the BR analysis (Ermondi and Caron, 2012)(Caron et al., 2013) which mandates the organization of the VS+ descriptors used for obtaining the PLS model into six blocks (namely, Size, Water, DRY, N1, O and Others, definitions and more details in Fig.1) of straightforward significance. In a very simplistic way, the BR analysis gives the relevance of the blocks to the model.

Fig. 1 outlines that the blocks have more or less the same relevance to the model ranging from 19% of the weight of all blocks played by the DRY (yellow in Fig. 1) to the 15% of the Others (in grey

in Fig. 1) block. Some blocks are positive (i.e Size, DRY, O and Others) and their height shows how much the property described by the block increases the interaction with mucin. Two blocks are prevalently negative (i.e. OH2 and N1) and indicate how much the property decreases the solutes skills in interacting with PGM.

Fig. 1. BR analysis output. The significance of any block is given in the corresponding colour code.

<insert Figure 1 here>

Fig. 1 supports that large dimensions (Size block in green) and solutes hydrogen bonding donor (HBD) properties (O block in red) promote the interaction of drugs with mucin. Conversely, hydrogen bonding acceptor (HBA) properties (blue block) are detrimental for the interaction. The contribution of solvation (described by the DRY and OH2 probes) to retention is in line with what found for few RP chromatographic systems (Ermondi and Caron, 2012) apart from a slightly higher relevance of the positive portion of the DRY block. This evidence and the mostly positive value of the Others block (Fig. 1) could be related to the highly hydrated and uniquely structured gel features of mucin.

The relevance of solutes HBD properties is in line with the experimental evidence that mucin molecules behave as anionic polyelectrolytes at neutral pHs (Sigurdsson et al., 2013). Moreover our model supports the crucial and detrimental role played by HBD properties in permeability studies (Potter et al., 2014).

Since lipophilicity is expected to be important in governing the interaction of drugs with mucin (Sigurdsson et al., 2013), we calculated $\log D_{\text{oct}}^{7.4}$, the logarithm of the distribution coefficient at pH 7.4 in the octanol/water system (MoKa software v.2.5.4, <http://www.moldiscovery.com>, was used). Then we plotted $\log k$ values (describing the interaction between drugs and mucin) vs $\log D_{\text{oct}}^{7.4}$. A poor relationship is found (data not shown).

Summing up, to limit mucus binding, drug candidates should have a limited number of HBD groups. However to avoid solubility issues the number of HBA groups can be increased. The design of new drugs for the treatment of a number of pathologies marked by mucus hyperproduction (e.g. cystic fibrosis) could be improved by the application of these simple rules to candidates selection.

Acknowledgements

The authors thank the University of Torino for financial support (ex60%).

References

Caron, G., Vallaro, M., Ermondi, G., 2013. The Block Relevance (BR) analysis to aid medicinal chemists to determine and interpret lipophilicity. *Medchemcomm* 4, 1376.

Ermondi, G., Caron, G., 2012. Molecular interaction fields based descriptors to interpret and compare chromatographic indexes. *J. Chromatogr. A* 1252, 84–9.

Ermondi, G., Visconti, A., Esposito, R., Caron, G., 2014. The Block Relevance (BR) analysis supports the dominating effect of solutes hydrogen bond acidity on $\Delta\log P(\text{oct-tol})$. *Eur. J. Pharm. Sci.* 53, 50–4.

Gargano, A.F.G., Lämmerhofer, M., Lönn, H., Schoenmakers, P.J., Leek, T., 2014. Mucin-based stationary phases as tool for the characterization of drug-mucus interaction. *J. Chromatogr. A* 1351, 70–81.


Hughes, J.P., Rees, S.S., Kalindjian, S.B., Philpott, K.L., 2011. Principles of early drug discovery. *Br. J. Pharmacol.* 162, 1239–1249.

Potter, T., Ermondi, G., Newbury, G., Caron, G., 2014. Relating Caco-2 permeability to molecular properties using block relevance analysis. *Med. Chem. Commun.* 4–7.

Sigurdsson, H.H., Kirch, J., Lehr, C.M., 2013. Mucus as a barrier to lipophilic drugs. *Int. J. Pharm.* 453, 56–64.

Valkó, K., 2004. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. *J. Chromatogr. A* 1037, 299–310.

Figure(s)



Supplementary Material

[Click here to download Supplementary Material: gcaron_ijp_BRmucin_SI.docx](#)

IJP AUTHOR CHECKLIST

Dear Author,

It frequently happens that on receipt of an article for publication, we find that certain elements of the manuscript, or related information, is missing. This is regrettable of course since it means there will be a delay in processing the article while we obtain the missing details.

In order to avoid such delays in the publication of your article, if accepted, could you please run through the list of items below and make sure you have completed the items.

Overall Manuscript Details

- Is this the final revised version? X
- Are all text pages present? X
- Are the corresponding author's postal address, telephone and fax numbers complete on the manuscript? X
- **Have you provided the corresponding author's e-mail address?** X
- **Manuscript type – please check one of the following:**
 - Full-length article
 - Review article
 - Rapid Communication
 - Note X
 - Letter to the Editor
 - Other
- **Manuscript section – paper to be published in:**
 - Pharmaceutical Nanotechnology section
 - Personalised Medicine section

Manuscript elements

- Short summary/abstract enclosed? X
- 3-6 Keywords enclosed? X
- Complete reference list enclosed? X
- Is the reference list in the correct journal style? X
- Are all references cited in the text present in the reference list? X
- Are all **original** figures cited in the text enclosed? X
 - Electronic artwork format? -----
- Are figure legends supplied? X
- Are all figures numbered and orientation provided? X
- Are any figures to be printed in colour?
 - If yes, please list which figures here:-----
- If applicable, are you prepared to pay for reproduction in colour?
- Are all tables cited in the text supplied? X

General

- Can you accept pdf proofs sent via e-mail? X